Granted Patent B2

US 12,491,177 · App. 18/150,993 · Granted Dec 9, 2025

Inventors: Michael Bristow (Englewood, CO); Christopher Dufton (Englewood, CO)

Assignee: GENVARA BIOPHARMA, INC.

A61K31/4045A61P9/06

Abstract

Claims (27)

1 . A method for treating atrial fibrillation, the method comprising administering an effective amount of bucindolol to an atrial fibrillation or atrial flutter patient who has been identified as having at least one atrial fibrillation event within six months of the administering, (a) has been tested and found to have a left ventricle ejection fraction of greater than 0.35 and no more than 0.6; and (b) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene.

2 . The method of claim 1 , wherein the patient has been diagnosed with atrial fibrillation less than 2 years before or after being diagnosed with heart failure.

3 . The method of claim 1 , wherein the patient is continually monitored for atrial fibrillation burden.

4 . The method of claim 1 , wherein the patient has had one or more clinical interventions of electrical cardioversion, administration of a Class III anti-arrhythmic drug, and/or catheter ablation.

5 . A method of treating atrial fibrillation, the method comprising administering an effective amount of bucindolol to a patient who:

(a) has been diagnosed with heart failure;

(b) has been tested and found to have a left ventricle ejection fraction of greater than 0.35 and no more than 0.6;

(c) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene; and

(d) was initially diagnosed with heart failure less than 12 years before the administering.

6 . The method of claim 5 , wherein the patient has been diagnosed with new onset, recurrent, or ongoing atrial fibrillation, atrial flutter, tachycardia, or cardiac arrhythmia.

7 . The method of claim 5 , wherein the patient has been diagnosed with is symptomatic atrial fibrillation or atrial flutter (AF/AFL).

8 . The method of claim 5 , wherein the patient has been diagnosed with new onset, recurrent, or ongoing atrial fibrillation or atrial flutter (AF/AFL).

9 . The method of claim 8 , wherein the recurrent atrial fibrillation is symptomatic and/or paroxysmal atrial fibrillation.

10 . The method of claim 5 , wherein the patient was initially diagnosed with atrial fibrillation less than 2 years before or after being diagnosed with heart failure.

11 . The method of claim 5 , wherein the patient was characterized as a class I or II heart failure patient.

12 . The method of claim 5 , wherein the patient was characterized as a class III heart failure patient.

13 . The method of claim 5 , wherein the patient has been tested and found to have a left ventricle ejection fraction of less than 0.6.

14 . A method of reducing atrial fibrillation burden, the method comprising administering an effective amount of bucindolol to a patient who:

(a) has been diagnosed with heart failure;

(b) has been tested and found to have a left ventricle ejection fraction of at least greater than 0.35 and no more than 0.6;

(c) has been genotyped and found to be homozygous for Arg389 in the ADRB1 gene; and

(d) was initially diagnosed with atrial fibrillation less than 2 years before or after being diagnosed with heart failure.

15 . The method of claim 14 , wherein the patient has had at least one episode of atrial fibrillation burden of more than 6 hours in a 24 hour period.

16 . The method of claim 14 , wherein atrial fibrillation burden is determined by electrocardiogram.

17 . The method of claim 14 , wherein the patient has symptomatic atrial fibrillation or atrial flutter (AF/AFL).

18 . The method of claim 14 , wherein the patient has recurrent, or ongoing atrial fibrillation or atrial flutter (AF/AFL).

19 . The method of claim 18 , wherein recurrent atrial fibrillation is symptomatic and/or paroxysmal atrial fibrillation.

Assignments (3)

Continuity (6)

References Cited (66)